Cox Christopher Nixon 4
4 · Alto Neuroscience, Inc. · Filed Feb 7, 2024
Insider Transaction Report
Form 4
Cox Christopher Nixon
Director
Transactions
- Conversion
Series B Preferred Stock
2024-02-06−1,250,000→ 0 total(indirect: By Lightswitch Capital Fund I, L.P.)→ Common Stock (588,898 underlying) - Conversion
Series C Preferred Stock
2024-02-06−281,917→ 0 total(indirect: By Lightswitch Capital Fund I, L.P.)→ Common Stock (126,755 underlying) - Conversion
Common Stock
2024-02-06+126,755→ 715,653 total(indirect: By Lightswitch Capital Fund I, L.P.) - Conversion
Common Stock
2024-02-06+588,898→ 588,898 total(indirect: By Lightswitch Capital Fund I, L.P.)
Footnotes (3)
- [F1]Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.
- [F2]The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.
- [F3]Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date.